Osteogenesis imperfecta

Cycling 850 kilometers in 8 days for kids

Retrieved on: 
Thursday, June 30, 2022
Neuromuscular Disorders, McGill University, Child, Research, Elective surgery, Education, GLOBE, Amelogenesis imperfecta, Glen, Rehabilitation, Awareness, Cerebral palsy, Shriners Hospitals for Children, RC, Hospital, Health, Osteogenesis imperfecta, Scoliosis, Telehealth, Physics, Health insurance, Shriners

MONTREAL, June 30, 2022 (GLOBE NEWSWIRE) -- From June 28 to July 5, 2022, Alex Rauket, member of the Bruce Shrine Club, will cycle 850 km in eight days.

Key Points: 
  • MONTREAL, June 30, 2022 (GLOBE NEWSWIRE) -- From June 28 to July 5, 2022, Alex Rauket, member of the Bruce Shrine Club, will cycle 850 km in eight days.
  • Associated with the Bruce Shrine Club, Alex has often pedaled for charity and has developed his endurance by cycling for increasingly longer distances.
  • In addition to my regular workouts, Ive been training by cycling 75 km a week after work.
  • You will see an entrance for Shriners Hospitals for Children Canada, go in and take the elevator up to RC.

OrthoPediatrics Corp. Announces Deal to Acquire Pega Medical

Retrieved on: 
Tuesday, June 14, 2022
Leadership, Original equipment manufacturer, Pega, Company, Scoliosis, Osteogenesis imperfecta, Lists of diseases, Elective surgery, Trauma, Telescope, Orthopediatrics, OI, Growth, GLOBE, Patient, Squadron Capital, Acquisition, Population, Surgeon, Deformity, University, Dentistry, Medicine, Pharmaceutical industry

David Bailey, Chief Executive Officer of OrthoPediatrics, commented, We are excited to announce the agreement to acquire Pega Medical.

Key Points: 
  • David Bailey, Chief Executive Officer of OrthoPediatrics, commented, We are excited to announce the agreement to acquire Pega Medical.
  • Similar to OrthoPediatrics, the Pega organization has been focused exclusively on addressing unmet needs for children whose lives have been impacted by musculoskeletal disorders and diseases.
  • OrthoPediatrics will acquire Pega Medical in a transaction valued up to $33 million.
  • Under the terms of the agreement, OrthoPediatrics will acquire Pega Medical for an upfront cash payment of $31 million plus $2 million in stock which includes certain restrictions for three years.

Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan

Retrieved on: 
Thursday, June 2, 2022
Company, Therapy, CRS, OI, DCR, Review, Osteogenesis imperfecta, Neoplasm, U.S. Securities and Exchange Commission, Șaeș, ORR, Forward-looking statement, Partnership, Monaco Age Oncologie, Ovarian cancer, SDS, Industry, Degenerative disease, PRS, EMA, Annual report, Security (finance), Senior, Cervical cancer, Patient, BOS, Form 6-K, PK, Program, Society, ASCO, Annual general meeting, American Society of Clinical Oncology, FDA, GLOBE, Uveal melanoma, NASDAQ, Respiratory tract, Safety, Pharmaceutical industry, Nivolumab, Ultragenyx, EU, AATD

LONDON and REDWOOD CITY, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced updated clinical data from its open-label Phase 1b/2 Study of Etigilimab and Nivolumab in subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE). The data will be presented in a poster session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting on June 5, 2022. The Company also provided an update on its capital allocation and portfolio prioritization plan.

Key Points: 
  • The data will be presented in a poster session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting on June 5, 2022.
  • The Company also provided an update on its capital allocation and portfolio prioritization plan.
  • Alvelestat for Alpha-1-Anti-Trypsin Deficiency (AATD): Mereo recently announced positive top-line data from the Phase 2 study of alvelestat in AATD.
  • Etigilimab in Oncology: Mereo intends to complete enrollment in the Phase 1b part of the previously planned Phase 1b/2 study in Q3 2022.

Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
BOS, Osteogenesis imperfecta, Company, OI, Uveal melanoma, Neoplasm, Annual general meeting, U.S. Securities and Exchange Commission, Partial-response maximum-likelihood, DCR, Monaco Age Oncologie, Poster, NASDAQ, Cervical cancer, Patient, Endpoint security, ORR, Degenerative disease, Society, American Society of Clinical Oncology, Form 6-K, Respiratory tract, PRS, SDS, Forward-looking statement, ASCO, Ovarian cancer, Tornado outbreak of February 10–11, 2009, Therapy, CR, Security (finance), Annual report, AATD, GLOBE, Pharmaceutical industry, Nivolumab

LONDON and REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the presentation of interim clinical data from its Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors in a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 3 – 7, 2022 in Chicago IL.

Key Points: 
  • We are very pleased that the interim results from our ACTIVATE study have been accepted for presentation at ASCO, said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo.
  • We look forward to sharing the updated data in our ASCO presentation with the oncology community.
  • The combination of etigilimab and nivolumab has been safe and well tolerated, with no new safety signals observed to-date.
  • The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

Retrieved on: 
Thursday, May 26, 2022
BOS, Osteogenesis imperfecta, OI, Company, Neoplasm, U.S. Securities and Exchange Commission, Patient, Monaco Age Oncologie, NASDAQ, ADSS, Degenerative disease, Respiratory tract, Form 6-K, Annual report, Intention, Forward-looking statement, Compliance, Ovarian cancer, Calendar, Therapy, LLC, American depositary receipt, Security (finance), Letter, AATD, GLOBE, Auction, Pharmaceutical industry, Nasdaq

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until November 21, 2022, to regain compliance with Nasdaqs minimum bid price requirement.

Key Points: 
  • Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until November 21, 2022, to regain compliance with Nasdaqs minimum bid price requirement.
  • If at any time during this period, the closing bid price of the Companys ADSs is at least $1.00 for a minimum of 10 consecutive business days, the Company will be deemed to have regained compliance.
  • Nasdaq will then provide a written confirmation of compliance and the matter will be closed.
  • Mereo intends to monitor the closing bid price of its ADSs.

An organization of women volunteers raises $6 million for Shriners Hospitals for Children - Canada

Retrieved on: 
Friday, May 20, 2022
B cell, BAHA, Osteogenesis imperfecta, Kool-Aid, Education, Scoliosis, Hospital, Shriners Hospital for Children – Canada, City, Rehabilitation, Family, Brace, Amelogenesis imperfecta, Shriners Hospitals for Children, Daughter of the Nile, Patient, Woman, Parent, Tibia, Health, Association, Director, Lists of diseases, Cerebral palsy, Research, Holiday, McGill University, Trustee, Telehealth, Time, Board, Motion, Leg, Daughter, GLOBE, Clubfoot, Glen, Health insurance, Shriners, Child

The Canadian Daughters of the Nile have reached $6 million raised to benefit the Shriners Hospitals for children - Canada.

Key Points: 
  • The Canadian Daughters of the Nile have reached $6 million raised to benefit the Shriners Hospitals for children - Canada.
  • Established in Montreal in 1925, Shriners Hospitals for Children Canada is the only Canadian establishment within the network of Shriners hospitals.
  • Locate the Shriners Hospitals for Children Canada entrance and take the elevator to the ground level.
  • Laure Moureaux, Communications Advisor, Shriners Hospitals for Children Canada.

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

Retrieved on: 
Wednesday, May 18, 2022
Part, Ruxolitinib, Osteogenesis imperfecta, SD, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, KROS, Patient, Part 1, Disorder, PAH, Therapy, Hypertensive emergency, Pharmacokinetics, Lists of diseases, COVID-19, Investor, Microdeletion syndrome, Volunteering, Bone loss, Cohort, Thrombocytopenia, Intellectual property, Anemia, Safety, Cytopenia, Osteoporosis, Alkaline phosphatase, Maintenance, BMP, Protein, SEC, Growth, Security (finance), GLOBE, Pharmaceutical industry, Vaccine, Medical imaging

The ongoing trial is designed as a randomized, double-blind, placebo-controlled, two-part trial to assess the safety, tolerability and pharmacokinetics of KER-012.

Key Points: 
  • The ongoing trial is designed as a randomized, double-blind, placebo-controlled, two-part trial to assess the safety, tolerability and pharmacokinetics of KER-012.
  • Additionally, the majority of the adverse events that were observed in Part 1 of this trial were mild in severity.
  • Preliminary topline results from Part 1 of this trial include the following:
    Pharmacokinetic parameters were observed to be generally dose proportional with increasing doses.
  • Following the completion of this Phase 1 clinical trial, Keros expects to initiate a Phase 2 clinical trial of KER-012 in patients with PAH, and expects to share the trial design for the Phase 2 clinical trial in early 2023.

Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors

Retrieved on: 
Tuesday, May 17, 2022
BOS, GCC1, Osteogenesis imperfecta, Company, Disease, Blood, OI, Neoplasm, X-linked hypophosphatemia, U.S. Securities and Exchange Commission, Genzyme, Sanofi, Doctor of Philosophy, Molecular biology, Leadership, Monaco Age Oncologie, Patient, NASDAQ, Vifor Pharma, KKI, Degenerative disease, Marketing, Respiratory tract, Novartis, Form 6-K, Forward-looking statement, Board, Ovarian cancer, Head, Therapy, Security (finance), University of Bristol, Annual report, AATD, GLOBE, Pharmaceutical industry

LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to the Companys Board of Directors, effective immediately.

Key Points: 
  • LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (Mereo or the Company), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to the Companys Board of Directors, effective immediately.
  • We are very excited to welcome Abdul to the Board at such a pivotal time for the Company, said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo.
  • I believe Abdul will be an asset to the Board and very much look forward to working with him.
  • Mereo has shown outstanding commitment to helping underserved patient populations and I am honored to be joining the Board, added Dr. Mullick.

Keros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association

Retrieved on: 
Thursday, May 12, 2022
Ruxolitinib, Osteogenesis imperfecta, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, MDS, 2021 Essex County Council election, KROS, Patient, European Hematology Association, Disorder, Therapy, Hypertensive emergency, Lists of diseases, COVID-19, Microdeletion syndrome, EHA, IIA, Bone loss, Thrombocytopenia, Intellectual property, FC, Anemia, Cytopenia, Osteoporosis, TGF, Maintenance, Security (finance), Protein, SEC, Growth, ALK2, GLOBE, Pharmaceutical industry

The following abstracts were posted to the EHA website on May 12, 2022, 10:00 a.m. Eastern time.

Key Points: 
  • The following abstracts were posted to the EHA website on May 12, 2022, 10:00 a.m. Eastern time.
  • Keros lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from iron imbalance.
  • Examples of these forward-looking statements include statements concerning: Keros presentation plans for the upcoming EHA annual meeting.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

Cortexyme Announces Agreement to Acquire Novosteo

Retrieved on: 
Tuesday, May 10, 2022
Research, Infectious Diseases, Dental, Biotechnology, Other Health, Health, Pharmaceutical, Science, Oncology, Board, Bone, U.S. Securities and Exchange Commission, Investment, Bone fracture, Forward-looking statement, Board of directors, IND, Nasdaq, Twitter, Birth, Osteogenesis imperfecta, Collagen, Director, Safety, Time, Patient, Doctor of Philosophy, Security (finance), Review, Degenerative disease, Wilson Sonsini Goodrich & Rosati, FDA, Periodontal disease, Cooley LLP, Therapy, Genetic code, Leadership, Osteoblast, CMO, Bone disease, SEC, CEO, News, Growth, Acquisition, Pharmaceutical industry, Management, Medical imaging

Upon completion of the transaction, Novosteo stockholders will own approximately 15.5% of the combined company.

Key Points: 
  • Upon completion of the transaction, Novosteo stockholders will own approximately 15.5% of the combined company.
  • We intend to capitalize on the combined assets of Novosteo and Cortexyme by driving our therapeutic candidates through development, expanding our targeted drug discovery platform, and pursuing new business development opportunities.
  • Cooley LLP acted as legal advisor to Cortexyme and Wilson Sonsini Goodrich & Rosati acted as legal advisor to Novosteo.
  • To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.